Ayala Pharmaceuticals (NASDAQ:AYLA) Receives “Market Perform” Rating from Noble Financial

Noble Financial reiterated their market perform rating on shares of Ayala Pharmaceuticals (NASDAQ:AYLAGet Rating) in a report released on Tuesday, The Fly reports.

Separately, HC Wainwright reduced their price objective on Ayala Pharmaceuticals from $18.00 to $12.00 and set a buy rating for the company in a research report on Tuesday, August 16th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $12.60.

Ayala Pharmaceuticals Stock Down 10.1 %

Shares of AYLA stock opened at $1.16 on Tuesday. The business has a 50 day moving average of $1.45 and a two-hundred day moving average of $2.14. Ayala Pharmaceuticals has a 52 week low of $0.70 and a 52 week high of $14.50. The company has a market cap of $17.13 million, a P/E ratio of -0.46 and a beta of 2.25.

Ayala Pharmaceuticals (NASDAQ:AYLAGet Rating) last issued its earnings results on Monday, August 15th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.11. Ayala Pharmaceuticals had a negative return on equity of 131.63% and a negative net margin of 1,749.29%. Analysts expect that Ayala Pharmaceuticals will post -2.33 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new stake in Ayala Pharmaceuticals during the 2nd quarter valued at $42,000. CSS LLC IL raised its stake in Ayala Pharmaceuticals by 98.7% during the 2nd quarter. CSS LLC IL now owns 64,180 shares of the company’s stock valued at $70,000 after purchasing an additional 31,878 shares during the period. Citadel Advisors LLC acquired a new stake in Ayala Pharmaceuticals during the 2nd quarter valued at $148,000. Finally, DLD Asset Management LP raised its stake in Ayala Pharmaceuticals by 9.2% during the 1st quarter. DLD Asset Management LP now owns 172,867 shares of the company’s stock valued at $688,000 after purchasing an additional 14,635 shares during the period. Institutional investors own 28.43% of the company’s stock.

Ayala Pharmaceuticals Company Profile

(Get Rating)

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.

Read More

The Fly logo

Analyst Recommendations for Ayala Pharmaceuticals (NASDAQ:AYLA)

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.